RESPONSE TO THE BIOLOGICAL WARFARE BW THREAT 20 AUG 90

File: 120396_sep96_decls54_0010.txt
Page: 0010
Total Pages: 16

Subject: RESPONSE TO THE BIOLOGICAL WARFARE BW THREAT 20 AUG 90          

Unit: OTSG        

Parent Organization: HSC         

Box ID: BX003201

Folder Title: OPERATION DESERT SHIELD RESPONSE TO THE BIOLOGICAL WARFARE BW THREAT                            

Document Number:          1

Folder SEQ  #:         45






         and ventilatory assistance may be required. Intensive and prolonged nursing
         care may be required for recovery (which may take several weeks).
               In isolated cases of foodbome botulism, circulating toxin is usually
         present, perhaps due to continued absorption through the gut wall. Equine
         antitoxin is used in these circumstances. After aerosol exposure, it is unknown
         whether toxin circulates or antitoxin would be therapeutically useful after onset
         of symptoms.

               V PROPHYLAXIS

               PRE-EXPOSURE

               VACCINE

               A pentavalent toxoid of Clostridium botulinum types A, B, C, D, and E
         has been produced, and is held in IND (Investigational New Drug) status. This
         product has been administered to several hundred volunteers and occupationally
         at-risk workers, and induces serum antitoxin levels which correspond to
         protective levels in experimental animal systems. The product must be
         administered several times over a 1-year period to induce solid antitoxin levels
         in an acceptable percentage of vaccinees. The currently recommended schedule
         (days 0, 14, 84, and 365) has not been modified for study. The little available
         data suggests that limited and transient antitoxin levels are induced after 3
         injections; there is no data currently available to assess immunogenicity after 1
         or 2 doses, although lower levels of antitoxin than those currently recommended
         for laboratory workers may well offer protection in a field setting. The
         immune response to 1 or 2 doses of vaccine is currently being evaluated.
               At present, this product is available in limited quantities, and must be
         administered under protocol. Contraindications include sensitivity to alum,
         formaldehyde, and thimerosal, or hypersensitivity to a previous dose.
T

Document 16 f:/Week-36/BX003201/OPERATION DESERT SHIELD RESPONSE TO THE BIOLOGICAL WARFARE BW THREAT/response to the biological warfare bw threat 20 :11229616342212
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003201
Unit = OTSG
Parent Organization = HSC
Folder Title = OPERATION DESERT SHIELD RESPONSE TO THE BIOLOGICAL WARFARE BW THREAT
Folder Seq # = 45
Subject = RESPONSE TO THE BIOLOGICAL WARFARE BW THREAT 20
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 22-NOV-1996